Role of metabolic crosstalk in determining immunity during tumor progression
Project Number5R01CA282794-02
Contact PI/Project LeaderANDERSON, ANA C Other PIs
Awardee OrganizationBRIGHAM AND WOMEN'S HOSPITAL
Description
Abstract Text
PROJECT SUMMARY
Tumor cells and infiltrating immune cells co-evolve during the course of tumor progression, with the immune
system progressively losing its efficacy as tumors advance. Immune cells are highly dependent on cellular
metabolism to manifest their effector functions, but in the tumor microenvironment (TME), ‘metabolic competition’
with rapidly proliferating cancer cells leads to nutrient deprivation alongside increased metabolic waste, both of
which negatively impact immune cell function. Moreover, ‘metabolic symbiosis’ between cancer and immune
cells can promote the acquisition of suppressive immune cell phenotypes, ultimately disfavoring anti-tumor
immunity. These dynamic metabolic interactions are shaped by the niches occupied by cells within the TME.
Thus, the metabolic cross talk between tumor and immune cells over the course of tumor progression can be a
major determinant of immune cell function and, consequently, response to immune-targeted therapies.
Unfortunately, the study of immune cell metabolism and crosstalk in the TME has been very challenging due to
reliance on methods that analyze metabolism in bulk cell populations, which obscures individual cellular diversity,
difficulties in predicting downstream outcomes of metabolic perturbations because of the complexity of the
metabolic network, and the lack of tools to map metabolic alterations in situ. To overcome these challenges, we
developed Compass, a flux balance analysis (FBA) algorithm that applies a network-based analytical approach
to single-cell RNA-sequencing (scRNA-seq) data to predict metabolic states of individual cells in tissue1. We
have applied Compass as well as standard computational methods to the analysis of longitudinal scRNA-seq
data from a pre-clinical murine model of melanoma with the goal of determining the temporal- and tumor-size-
based metabolic alterations in both tumor and infiltrating immune cells during tumor progression.
Our preliminary data indicate that polyamine metabolism is a key hub of metabolic crosstalk between tumor and
immune cells that are either static or dynamic over the course of melanoma tumor progression and that may
occupy distinct tissue niches. We find that CD4+ regulatory T cells (Treg), exhausted CD8+ T cells, and
suppressive myeloid cells upregulate spermine/spermidine acetyltransferase (Sat1), which catalyzes acetylation
of polyamines, with tumor progression. Conversely, a subset of c-Met+ melanoma cells that has features of
stemness is high for polyamine recycling genes. Based on these observations, we hypothesize that that
systems-based analysis of the alterations and crosstalk involving polyamine metabolism in tumor and
immune cells during tumor progression will uncover novel means for therapeutic intervention. We
propose to: 1) Dissect the functional role of polyamine metabolism in immune cells and tumor cells during tumor
progression; 2) Construct a high resolution spatial map of tumor:immune metabolic crosstalk via the polyamine
pathway.
Public Health Relevance Statement
NARRATIVE STATEMENT
Cancer is a significant cause of morbidity and mortality worldwide. The immune system has the capacity to fight
cancer, but it becomes disabled as cancer progresses. The proposed studies will advance our knowledge of how
tumor cells and immune cells influence each other’s metabolism over the course of tumor progression with the
goal of devising new anti-cancer therapies.
No Sub Projects information available for 5R01CA282794-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01CA282794-02
Patents
No Patents information available for 5R01CA282794-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01CA282794-02
Clinical Studies
No Clinical Studies information available for 5R01CA282794-02
News and More
Related News Releases
No news release information available for 5R01CA282794-02
History
No Historical information available for 5R01CA282794-02
Similar Projects
No Similar Projects information available for 5R01CA282794-02